Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

InteRNA Technologies Receives Notice of Allowance for miRNA Sequences of its Lead Pre-Clinical Product

Published: Monday, October 15, 2012
Last Updated: Monday, October 15, 2012
Bookmark and Share
Patent covers the precursor and mature sequences of miRNA-3157, the Company's lead product in its B-Raf/melanoma program.

InteRNA Technologies B.V. announces that the United States Patent and Trademark Office (USPTO) has issued the Company a notice of allowance on a patent application covering miRNA sequences, identified through deep sequencing of several different mouse, monkey and human samples, including different tumor samples. The allowable product claims protect miRNA-3157, homologues, precursors and mimics thereof. In a second pending patent application, miRNA-3157, homologues, precursors and mimics thereof are claimed as a therapy against melanoma. A mimic of miRNA-3157 is entering preclinical development and represents InteRNA's lead product in its B-Raf/melanoma program.

"This issuance of the USPTO confirms our unique approach to identification and validation of miRNAs as drug targets and further development towards the clinic", said Roel Schaapveld, CEO of InteRNA Technologies. "It further subscribes our patent strategy and greatly strengthens our intellectual property position on miRNA drug candidates."

The latest data on miRNA-3157 as drug candidate for the treatment of human melanoma will be presented at the Society for Melanoma Research 2012 Congress, November 8-11 in Hollywood, CA, USA.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

InteRNA Technologies Secures Final Extension Series A Financing
Company has announced Hans Schikan as new chairman of its Supervisory Board.
Saturday, October 31, 2015
InteRNA Technologies, UCB and University of Bonn to Collaborate
Agreement on the role of microRNAs in neurodegenerative disease.
Friday, January 10, 2014
MiRacle Consortium Receives a € 1.2 Million FP7 Grant from the European Union
Therapeutic development of cancer cell-specific targeting of novel tumor-selective lethal miRNAs for the treatment of head and neck cancer – acronym: MiRacle.
Monday, November 04, 2013
InteRNA Technologies Announces Closing of Equity Financing Round
Company secures additional equity financing to progress lead program for melanoma treatment.
Friday, September 06, 2013
InteRNA Technologies Receives Notice of Allowance from USPTO
Patent covers the precursor and mature sequences of miRNA-3157, the Company's lead product in its B-Raf/melanoma program.
Tuesday, October 16, 2012
Scientific News
Advancing Synthetic Biology
Living systems rely on a dizzying variety of chemical reactions essential to development and survival. Most of these involve a specialized class of protein molecules — the enzymes.
NIH Researchers Identify Striking Genomic Signature for Cancer
Institute has identified striking signature shared by five types of cancer.
CRI Develops Innovative Approach for Identifying Lung Cancer
Institute has developed innovative approach for identifying processes that fuel tumor growth in lung cancer patients.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
Cancer Cells Kill Off Healthy Neighbours
Cancer cells create space to grow by killing off surrounding healthy cells, according to UK researchers working with fruit flies.
Cancer Drug Target Visualized at Atomic Resolution
New study using cryo-electron microscopy shows how potential drugs could inhibit cancer.
Genetic Mechanism Behind Cancer-Causing Mutations
Researchers at Indiana University has identified a genetic mechanism that is likely to drive mutations that can lead to cancer.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
"Gene Fusion" Drives Childhood Brain Cancers
Study co-led by Penn scientists highlights potential targets for future cancer therapies.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!